September 2019 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2021 Concepts

Harnessing Natural Killer (NK) Cells To Prevent, Control, or Eradicate HIV

For the published request for applications, see the March 6, 2020, Guide announcement, Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (R01 Clinical Trial Not Allowed)

Novel Therapeutics Directed to Intracellular HIV Targets

For the published request for applications, see the December 19, 2019, Guide announcement, Novel Therapeutics Directed to Intracellular HIV Targets (R21, Clinical Trial Not Allowed).

Long-Acting Treatments for HIV and HIV-Associated Co-Infections

For the published request for applications, see the March 23, 2020 Guide announcement, Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33, Clinical Trial Not Allowed).

Transgender People: Immunity, Prevention, and Treatment of HIV and STIs

For the published program announcement with special receipt, referral, and/or review considerations, see the November 12, 2019, Guide announcement, Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21, Clinical Trial Not Allowed).

Engineering Immunity Through Vaccines

For the published request for applications, see the March 9, 2020, Guide announcement, Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61/R33, Clinical Trial Not Allowed).

Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD)

For the published program announcement with special receipt, referral, and review considerations, refer to the March 3, 2020, Guide announcement, Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD), (U19 Clinical Trial Not Allowed)

Preclinical and Translational Vaccine Development Support for HIV and Other Candidate Agents

For the published request for proposals, see the April 10, 2020 solicitation, Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents.

Content last reviewed on